Supplementary Fig. S6. Targeting MCT-1 and tocilizumab treatment together suppress 4T1 cancer stemness. MCT-1 (A), CD133 (B), Snail (C), Nanog (D) and Oct-4 (E) mRNA levels in the 4T1 mammospheres were evaluated after tocilizumab (200 µg/ml) treatment for 9 days. The results are expressed as the mean ± SD (n=3). (*p<0.05; **p<0.01; *** p<0.001).